Press release
ENPICOM launches versatile display data analysis solution to accelerate antibody selection while maximizing precision
ENPICOM, an innovative bioinformatics software company, announced the upcoming expansion of the capabilities of the IGX Platform to unlock seamless analysis of antibody panning data. This major development will allow researchers to analyze antibody display data in an intuitive and visual way, easily perform multi-dataset comparisons, and identify a diverse set of enriched candidates with the best characteristics."Our customer-centric approach to product development gives us a close-up view of the complex analysis workflows required for antibody display screening and how a single, scalable tool can immensely improve speed of analysis and quality of the selected candidates." said Jos Lunenberg, co-founder and Chief Executive Officer at ENPICOM. "Due to limited, inefficient workflows researchers often have to discard the vast majority of the available NGS data and focus on a small pool of the most frequent clones. We are launching the new IGX-Track App so that our customers can look beyond the tip of the iceberg and make informed decisions with a complete view of their data. Custom analysis workflows and visualizations can be created with a few clicks so scientists can simply select better antibodies faster."
Enabling streamlined enrichment analysis
Display technologies empower antibody discovery by screening millions of candidates against potential targets. By including different panning round conditions and a variety of antigens, researchers can obtain a robust candidate pool with diverse binding profiles. However, complex analysis workflows - including operations like intersecting, joining, or subtracting datasets - that match the panning campaign design are needed to fully take advantage of the powerful combination of NGS and display screening.
The new IGX-Track App extends the antibody discovery capabilities of the IGX Platform and provides a fast, flexible way to discover a diverse set of enriched candidates with the best characteristics. Scientists can effortlessly compose enrichment analysis workflows that match the design of their panning campaigns and discover candidates that otherwise would have been overlooked.
Scientists using IGX-Track on the IGX Platform will be able to:
- Track clones across panning rounds to identify highly enriched candidates through tabular views and interactive, user-defined visualizations.
- Freely join, intersect, and subtract many datasets to match their panning campaign design.
- Broaden their analysis beyond just the most frequent clones with the platform's scalable, NGS-ready architecture.
- Easily subtract irrelevant antibodies identified in control panning conditions from the candidates enriched on target.
- Make fully informed choices, while avoiding bias, by overlaying accurate liability predictions, assay data, and more onto enrichment graphs.
The company will launch the new functionality at the Antibody Engineering and Therapeutics conference on June 8 in Amsterdam. Sign up here to watch their presentation and learn more.
ENPICOM BV
Sint Janssingel 88
5211DA, 's-Hertogenbosch
communications@enpicom.com
+31 85 250 0575
About ENPICOM
ENPICOM is an innovative bioinformatics software engineering company delivering ground-breaking products and customized solutions to decode the immune system and improve human health. With a diverse team of over 45 experts in various disciplines, ENPICOM serves customers from all over the world, ranging from academic research centers doing basic research related to the immune system, to biotech and global pharmaceutical companies focusing on the discovery and development of novel immunotherapies and vaccines.
Leveraging a unique mix of immunology knowledge, bioinformatics method development, and software engineering skills, ENPICOM offers a world-class repertoire sequencing data analysis solution - the ImmunoGenomiX (IGX) Platform. IGX is an innovative platform to manage, store, analyze, visualize, and interpret immune repertoire sequencing data from T and B cell receptors. Together with its partners, ENPICOM delivers full immune repertoire sequencing and analysis service.
For more information, visit enpicom.com.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ENPICOM launches versatile display data analysis solution to accelerate antibody selection while maximizing precision here
News-ID: 2639300 • Views: …
More Releases from ENPICOM

ENPICOM launches unified bioinformatics platform for lab and AI scientists
's-Hertogenbosch, The Netherlands, October 1, 2024 - ENPICOM, an innovative bioinformatics software engineering company, announces the launch of its new unified bioinformatics solution designed to accelerate biologics discovery and development. The ENPICOM Platform seamlessly integrates AI, data management, and machine learning (ML) frameworks to foster collaboration among lab scientists, data scientists, and ML experts to drive innovation in biologics research.
"The question is no longer whether AI will change our lives,…

ENPICOM secures financing from BOP Capital, BOM Brabant Ventures and brings Dr. …
's-Hertogenbosch, Netherlands - March 21, 2024 - ENPICOM, an innovative bioinformatics software solutions provider, has reached a major milestone by securing additional growth capital from its current investors, BOP Impact Ventures and BOM Brabant Ventures, aimed at expanding the development of ENPICOM's AI assets. Furthermore, the company proudly welcomes Dr. Colby Souders, a seasoned expert in antibody discovery, to its group of investors. This infusion of growth capital not only…

ENPICOM secures extended financing from BOP Capital, BOM Brabant Ventures, Nextg …
s-Hertogenbosch, The Netherlands, June 28, 2023 - ENPICOM, an innovative bioinformatics software engineering company, has successfully secured further financial backing from its current investors BOP Capital, BOM Brabant Ventures, Nextgen Ventures, and Arches Capital. This underscores investor confidence in ENPICOM's vision, unique technological capabilities, and exceptional track record in serving customers in the pharmaceutical and biotech industries.
Recognizing the need for innovative data analysis solutions that provide a comprehensive understanding of…

ENPICOM secures Series B funding to scale up operations to meet the high demand …
ENPICOM, an innovative bioinformatics software engineering company, today announced closing of a capital investment round led by BOP Capital. With this additional growth capital, the company can support the rapidly expanding customer base for its unique SaaS proposition, the IGX Platform, to boost the candidate selection processes related to therapeutic antibody discovery. ENPICOM saw a rapid market uptake of its Antibody Discovery Module by Pharma, Biotech and CRO’s after launch…
More Releases for IGX
ENPICOM secures Series B funding to scale up operations to meet the high demand …
ENPICOM, an innovative bioinformatics software engineering company, today announced closing of a capital investment round led by BOP Capital. With this additional growth capital, the company can support the rapidly expanding customer base for its unique SaaS proposition, the IGX Platform, to boost the candidate selection processes related to therapeutic antibody discovery. ENPICOM saw a rapid market uptake of its Antibody Discovery Module by Pharma, Biotech and CRO’s after launch…
ENPICOM introduces a powerful liability prediction solution to de-risk antibody …
‘s-Hertogenbosch, The Netherlands, September 7, 2021 – ENPICOM, an innovative bioinformatics software company, announced today at the Biologics UK conference new IGX Platform capabilities to accurately annotate exposed liabilities, perform structural modeling of antibodies at scale, and determine developability profiles using customizable penalties. This major development allows researchers to improve their candidate selection by making accurate developability predictions for thousands of sequences at the same time, in a secure, intuitive…
Zai Lab selects ENPICOM’s IGX Platform to leverage new NGS-powered antibody di …
‘s-Hertogenbosch, The Netherlands, May 27, 2021 – ENPICOM, an innovative bioinformatics software engineering company, announced today that Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative, research-based, commercial-stage biopharmaceutical company based in China and the U.S., has signed a subscription agreement for ENPICOM’s IGX Platform. The IGX Platform with its Antibody Discovery Module (ADM) is a software platform engineered to assist researchers in diversifying and improving their candidate pools by…
ENPICOM and MiLaboratories join forces to power better Repertoire Sequencing dat …
‘s-Hertogenbosch (The Netherlands) and Solana Beach, CA (United States), December 15, 2020 - ENPICOM BV, an innovative bioinformatics software engineering company, and MiLaboratories LLC, a technology leader in profiling the mammalian adaptive immune system, announced a strategic partnership to enable efficient MiXCR integration into ENPICOM’s cloud-based IGX Platform.
Combining the best of both software solutions within a single platform
MiXCR is a universal, state-of-the-art software solution for annotation and quantification of large-scale…
ENPICOM services Neogene Therapeutics with its T cell repertoire sequencing data …
ENPICOM B.V., an innovative bioinformatics software engineering company delivering ground-breaking products and customized solutions to decode the immune system and improve human health, today announced the company has entered into a service agreement with Neogene Therapeutics to grant the company access to ENPICOM’s cloud-based IGX Platform to manage, organize, and analyze T cell sequencing data. ENPICOM has additionally developed a number of customizations making sure that the platform’s functionality fits…
University Health Network, Canada’s largest research hospital, selects ENPICOM …
The Princess Margaret Cancer Centre, one of the top five cancer research centers in the world, uses ENPICOM’s software to gain insights from the immune system and predict treatment responses in cancer patients
‘s-Hertogenbosch (The Netherlands), September 16, 2020 – ENPICOM, an innovative bioinformatics software engineering company specialized in decoding the immune system, announced that the Princess Margaret Cancer Centre of the University Health Network (UHN) has purchased a subscription to…